Viridian Therapeutics Inc
NASDAQ:VRDN

Watchlist Manager
Viridian Therapeutics Inc Logo
Viridian Therapeutics Inc
NASDAQ:VRDN
Watchlist
Price: 20.2 USD 2.96% Market Closed
Market Cap: 1.5B USD
Have any thoughts about
Viridian Therapeutics Inc?
Write Note

Viridian Therapeutics Inc
Additional Paid In Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Viridian Therapeutics Inc
Additional Paid In Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Additional Paid In Capital CAGR 3Y CAGR 5Y CAGR 10Y
Viridian Therapeutics Inc
NASDAQ:VRDN
Additional Paid In Capital
$1.4B
CAGR 3-Years
57%
CAGR 5-Years
51%
CAGR 10-Years
43%
Abbvie Inc
NYSE:ABBV
Additional Paid In Capital
$21.2B
CAGR 3-Years
5%
CAGR 5-Years
7%
CAGR 10-Years
18%
Gilead Sciences Inc
NASDAQ:GILD
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Additional Paid In Capital
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Additional Paid In Capital
$6.9B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
2%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Additional Paid In Capital
$12.7B
CAGR 3-Years
17%
CAGR 5-Years
24%
CAGR 10-Years
18%
No Stocks Found

Viridian Therapeutics Inc
Glance View

Market Cap
1.6B USD
Industry
Biotechnology

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. The company is headquartered in Waltham, Massachusetts and currently employs 86 full-time employees. The company went IPO on 2014-06-18. The firm is engaged in developing three product candidates, VRDN-001, VRDN-002, and VRDN-003, that is developed for intravenous (IV) or subcutaneous administration to treat patients who suffer from thyroid eye disease (TED). Its lead product candidate, VRDN-001, is a differentiated humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the TED. The company has initiated a Phase I/II clinical trial of VRDN-001. Its second product candidate, VRDN-002, is a distinct IGF-1R antibody that incorporates half-life extension technology, and is designed to support administration as a convenient, low volume, subcutaneous injection to treat patients who suffer from TED. VRDN-003 is an anti-IGF-1R monoclonal antibody with the same amino acid sequence as VRDN-001.

VRDN Intrinsic Value
7.68 USD
Overvaluation 62%
Intrinsic Value
Price

See Also

What is Viridian Therapeutics Inc's Additional Paid In Capital?
Additional Paid In Capital
1.4B USD

Based on the financial report for Sep 30, 2024, Viridian Therapeutics Inc's Additional Paid In Capital amounts to 1.4B USD.

What is Viridian Therapeutics Inc's Additional Paid In Capital growth rate?
Additional Paid In Capital CAGR 10Y
43%

Over the last year, the Additional Paid In Capital growth was 78%. The average annual Additional Paid In Capital growth rates for Viridian Therapeutics Inc have been 57% over the past three years , 51% over the past five years , and 43% over the past ten years .

Back to Top